Stock Market Impact: Shares dropped approximately 10% after CEO Mike Mahoney indicated flat US Watchman revenue and a decline in standalone Watchman procedures, raising concerns over near‑term market sentiment.
Listed Companies and Sectors: Boston Scientific Corp (medical‑device maker) retains a 91% market share in the Watchman left‑atrial appendage closure device but faces competitive pressures in electrophysiology (second‑largest globally), cardiac rhythm management (leadless gap), and urology (price‑competitive niche players and disruption from Axonics). The company reaffirmed full‑year organic growth guidance of 6.5%‑8% and Q2 guidance of 5%‑7%, though analysts now anticipate outcomes near the lower ends of those ranges.
Investment Flows: No specific FDI/FPI measures mentioned; however, Bloomberg Intelligence estimates slower Watchman sales could reduce total revenue by 0.8‑1.3 percentage points, potentially influencing investor sentiment.
Interest Rates, Inflation, and Liquidity: Not addressed in the article.
Fiscal or Monetary Policy: Not addressed in the article.
